Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 2
---
110
in recurrent glioblastoma. We have completed and announced the results of two Phase 1 studies in DMG. There is an ongoing Phase 1 investigator-initiated
trial in medulloblastoma.

Our
clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of
drugs through either sustained delivery (Q-Sphera TM TM TM

  Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                 
  is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                          

  MidaCore platform: Our gold nanoparticle nanotechnology is used                                      

We are currently focused on
our clinical stage assets and there are no active research and development programs based on our drug delivery technologies.

Revenue. Revenue for
the whole of the Company for the years ended December 31, 2024, 2023 and 2022 is set out below.

                                                                 Year ended December 31,                                        
  (£ in thousands)                                                                  2024      2023               2022           
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue (Europe, including United Kingdom)                                                            381                699  
  Revenue (Rest of World)                                                                               --                 --   
  Total Revenue from continuing and discontinued operations                                             381                699  

  52  

  Table of Contents  

Recent Developments